MIRA
INFORM REPORT
|
Report Date : |
02.11.2011 |
IDENTIFICATION DETAILS
|
Name : |
INTERNATIONAL CENTRE FOR GENETIC ENGINEERING AND BIOTECHNOLOGY |
|
|
|
|
Registered
Office : |
ICGEB Campus, ICGE B P O Box 10504, Aruna Asaf Ali Marg, New
Delhi-110067 |
|
|
|
|
Country : |
India |
|
|
|
|
Financials (as
on) : |
Not Available |
|
|
|
|
Year of
Establishment: |
1983 |
|
|
|
|
Capital
Investment / Paid-up Capital : |
Not Divulged |
|
|
|
|
Legal Form : |
UNIDO Aided Research Center |
|
|
|
|
Line of Business
: |
The centre conducts innovative research in the life sciences and
provides a scientific and educational environment of the highest standard. |
|
|
|
|
No. of Employees
: |
400 [Approximately] |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
Unknown |
|
|
|
|
Litigation : |
Clear |
|
|
|
|
Comments : |
Subject is an established Research Institute of Genetic Engineering
and Biotechnology aided by the United Nations Industrial Development Organization
(UNIDO). The centre conducts innovative research in the life sciences and
provides a scientific and educational environment of the highest standard.
Trade relations are reported as fair. Payments are unknown. The centre can be considered normal for business dealings at usual
trade terms and conditions. |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List – September 30, 2011
|
Country Name |
Previous Rating (30.06.2011) |
Current Rating (30.09.2011) |
|
|
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low |
A2 |
|
Moderate |
B1 |
|
High |
B2 |
|
Very High |
C1 |
|
Restricted |
C2 |
|
Off-credit |
D |
LOCATIONS
|
Registered Office : |
ICGEB Campus, ICGE B P O Box 10504, Aruna Asaf Ali Marg, New
Delhi-110067, India |
|
Tel. No.: |
91-11-26741358/26742357/59/60/61 |
|
Fax No.: |
91-11-26742316 |
|
E-Mail : |
|
|
Website : |
|
|
Area : |
3720 Sq. Mt. |
|
|
|
|
Head Quarters: |
Cod.
Fisc. 90031700322, Area Science Park, Padriciano 99, 34149 Trieste, Italy |
|
Tel. No.: |
+39-040-37571 |
|
Fax No.: |
+39-040-226555 |
|
E-Mail : |
|
|
|
|
|
Branches : |
Located At: ·
Cape Town ·
South Africa |
MANAGEMENT TEAM
|
Name : |
Prof. Virander S. Chauhan |
|
Designation : |
Director |
|
|
|
|
Name : |
Dr. S. Natesh |
|
Designation : |
Advisor (Liaison Officer) |
|
Address : |
Department of Biotechnology, Ministry of
Science and Technology, Government of India, Block 2, CGO Complex,
Lodhi Road, New Delhi-110003, India |
|
Tel No.: |
91-11-24364064 |
|
Fax No.: |
91-11-24362884 / 24363018 |
|
Email: |
BUSINESS DETAILS
|
Line of Business : |
The centre conducts innovative research in the life sciences and
provides a scientific and educational environment of the highest standard. |
|
|
|
|
Terms : |
|
|
Selling : |
Cash and Credit |
|
|
|
|
Purchasing : |
Cash and Credit |
GENERAL INFORMATION
|
No. of Employees : |
400 [Approximately] |
|
|
|
|
Bankers : |
Not Available |
|
|
|
|
Banking
Relations : |
-- |
|
|
|
|
Auditors : |
Not Available |
CAPITAL STRUCTURE
Note: The current total funding level of
the ongoing national grants is Rs 861.56 million (USD17.70 million) and for
international grants it is USD 9.17 million.
FINANCIAL DATA
[all figures are in
Rupees Millions]
NOT AVAILABLE
LOCAL AGENCY FURTHER INFORMATION
NOTE: UNIDO is the
specialized agency of the United Nations that promotes industrial development
for poverty reduction, inclusive globalization and environmental
sustainability.
|
Check List by Info
Agents |
Available in Report
(Yes / No) |
|
1) Year of Establishment |
Yes |
|
2) Locality of the firm |
Yes |
|
3) Constitutions of the firm |
Yes |
|
4) Premises details |
Yes |
|
5) Type of Business |
Yes |
|
6) Line of Business |
Yes |
|
7) Promoter's background |
-- |
|
8) No. of employees |
Yes |
|
9) Name of person contacted |
No |
|
10) Designation of contact person |
No |
|
11) Turnover of firm for last three years |
No |
|
12) Profitability for last three years |
No |
|
13) Reasons for variation <> 20% |
No |
|
14) Estimation for coming financial year |
No |
|
15) Capital in the business |
Yes |
|
16) Details of sister concerns |
No |
|
17) Major suppliers |
No |
|
18) Major customers |
No |
|
19) Payments terms |
No |
|
20) Export / Import details (if applicable) |
No |
|
21) Market information |
-- |
|
22) Litigations that the firm / promoter involved in |
-- |
|
23) Banking Details |
No |
|
24) Banking facility details |
No |
|
25) Conduct of the banking account |
-- |
|
26) Buyer visit details |
-- |
|
27) Financials, if provided |
Yes |
|
28) Incorporation details, if applicable |
-- |
|
29) Last accounts filed at ROC |
-- |
|
30) Major Shareholders, if available |
-- |
WEBSITE DETAILS:
The
Delhi component is located within the subject Campus in South Delhi, which
comprises an area of 10,000 square metres. It is situated alongside the
Jawaharlal Nehru University and the Sanjay Van in a bush forest area. The
Laboratories comprise a main building, a Guest house facility,
Bioexperimentation Unit, BSL-3 Facility, and a number of greenhouses for
agriculture related research.
The
subject extension laboratory, covering an area of over 3,720 square metres, has
been created to decongest the workspace in the existing building. All of the
Groups working on malaria, tuberculosis and bioinformatics have shifted to the
new wing. The new Group, Synthetic Biology and Biofuel, is also placed here.
RESEARCH
The
main research areas at Subject New Delhi Labs focus on mammalian and plant
biology. Biomedical projects are pursued in virology (hepatitis B and E
viruses, human immunodeficiency virus and SARS virus), immunology (biology of
the immune response and tuberculosis), development of diagnostics and vaccine
candidates for dengue viral infection, structural biology (development of
synthetic antibiotics, crystal structure determination of proteins and
polypeptides) and in the field of malaria both in basic research and vaccine
and drug development, as well as development of technologies for
biopharmaceuticals and for diagnosis of infectious diseases. In the plant
biology area, research projects address the study of insect resistance and
biopesticidals, abiotic and biotic plant stresses and crop improvement through
biotransformation.
Subject New Delhi has 36 Principal Investigators distributed in 9
different Research Groups. The Component also has a flourishing PhD programme
in association with the Jawaharlal Nehru University (JNU) and at any given time
has up to 100 PhD students. In addition, there are approximately 100 junior
scientists working in various extra-mural funded research projects. Subject PIs
have obtained research grants from various funding agencies within the country
as well as extra-mural funds from international agencies, such as The Wellcome
Trust, European Malaria Vaccine Initiative, European Commission, International
Aids Vacine Initiative, National Institute of Health, Bill and Melinda Gates
Foundation, Dupont and Pepsico. The current total funding level of the ongoing
national grants is Rs 861.56 million (USD17.70 million) and for international
grants it is USD 9.17 million.
An innovative collaboration programme has also been established with the
Emory Global Vaccine Centre that will focus on the development of vacines
against diseases such as tuberculosis and malaria. The Malaria Group also has a
research collaboration programme with the internationally renowned company,
Genzyme India, for malaria drug development.
THE SITE
The Headquarters of the
Centre, located in Trieste (Italy), coordinate the research programmes of the
three Components located in Trieste, Italy, New Delhi, India and Cape Town,
South Africa, and provide the foundation upon which the Subject training and
institutional activities are implemented. An Outstation is located
in Monterotondo, Rome.
The Subject
Training programme comprises both short-term training
(monothematic courses on specific subjects at the forefront of scientific
research) and long-term
training activities aimed at hands-on capacity-building of
scientists, and which are fully incorporated within the work of the research
groups. The Subject
also operates through an international
PhD programme jointly developed with academic institutions of world
renown.
Subject
Headquarters also coordinate the Collaborative Research Programme, a unique
resource of funding aimed at financing research projects implemented in Member
States, as well as the relationship between the Centre and its industrial
partners, ensuring the transfer of technologies developed at its Components.
Subject
fosters innovative approaches for industrial relations at a global level and
enhances joint ventures and other partner-oriented approaches for the
commercialisation of biotechnology. Furthermore, the Centre provides its
constituency with a number of institutional activities on issues at the
borderline between science and the policy of science, such as biosafety, intellectual
property rights and ethics of science.
GENERAL INFORMATION
ABOUT THE CENTRE
Subject provides a scientific and educational
environment of the highest standard and conducts innovative research in life sciences for the
benefit of developing countries. It strengthens the research capability of its
Members through training
and funding programmes
and advisory services and represents a comprehensive approach to promoting
biotechnology internationally.
The Centre is dedicated to advanced research
and training in molecular biology and biotechnology and holds out the prospect
of advancing knowledge and applying the latest techniques in the fields of:
·
Biomedicine
·
Crop improvement
·
Environmental protection/remediation
·
Biopharmaceuticals and biopesticide production
With Components in Trieste,
Italy, New Delhi, India and Cape Town, South Africa, the Centre forms an
interactive network with Affiliated Centres in Subject Member States. Subject
is part of the United Nations System.
FACTS AND FIGURES
The Board of Governors, made up of
representatives from each Member State, the Council of Scientific Advisers,
composed of eminent scientists who oversee the scientific excellence of the
Centre, and the Secretariat, which is constituted by the Director-General,
Prof. Franciso E. Baralle, the Directors of the three Components, Prof. Mauro
Giacca - Director ICGEB Trieste, Prof. Virander S. Chauhan - Director ICGEB New
Delhi, Prof. Iqbal Parker - Director ICGEB Cape Town and by the Director
Administration and External Relations, Mr. Decio Ripandelli.
At present more
than 400 people from 38 different countries are working in the Subject
laboratories as research scientists, postdoctoral fellows, PhD students,
research technicians and administrative personnel.
HISTORY
1983 - The Subject was
launched with the signing of its Statutes (the international treaty sanctioning
its existence, deposited with the Secretary General of the United Nations) by
26 countries during a Plenipotentiary Meeting, held in Madrid.
1984 - The representatives
of the Signatory Countries met in Vienna and decided that Subject would be
structured with two Components, one located in Trieste, Italy (which would also
be the Headquarters of the Centre), and one in New Delhi, India, as well as a
network of Affiliated Centres.
1987 - Pending the
entry into force of the Statutes, Subject started operations as a special
programme of the United Nations Industrial Development Organization (UNIDO).
The implementation of the programme was made possible through funds provided by
the Host Governments of Italy and India.
1994 - The Statutes of
the Centre entered into force on 3 February, and, in accordance with Article 1,
the Subject became an autonomous, intergovernmental organisation.
2007 - The Third
Component of the Subject is established in Cape Town, South Africa.
2011 - The Subject currently has 61 full
Member States, a further 22 countries are still pending ratification of, or
accession to, the Statutes of Subject.
CMT REPORT (Corruption, Money Laundering & Terrorism]
The Public Notice information has been collected from various sources
including but not limited to: The Courts,
1] INFORMATION ON
DESIGNATED PARTY
No exist designating subject or any of its beneficial owners,
controlling shareholders or senior officers as terrorist or terrorist
organization or whom notice had been received that all financial transactions
involving their assets have been blocked or convicted, found guilty or against
whom a judgement or order had been entered in a proceedings for violating
money-laundering, anti-corruption or bribery or international economic or
anti-terrorism sanction laws or whose assets were seized, blocked, frozen or
ordered forfeited for violation of money laundering or international
anti-terrorism laws.
2] Court Declaration :
No records exist to suggest that subject is
or was the subject of any formal or informal allegations, prosecutions or other
official proceeding for making any prohibited payments or other improper
payments to government officials for engaging in prohibited transactions or
with designated parties.
3] Asset Declaration :
No records exist to suggest that the property or assets of the subject
are derived from criminal conduct or a prohibited transaction.
4] Record on Financial
Crime :
Charges or conviction
registered against subject: None
5] Records on Violation of
Anti-Corruption Laws :
Charges or
investigation registered against subject: None
6] Records on Int’l
Anti-Money Laundering Laws/Standards :
Charges or
investigation registered against subject: None
7] Criminal Records
No
available information exist that suggest that subject or any of its principals
have been formally charged or convicted by a competent governmental authority
for any financial crime or under any formal investigation by a competent
government authority for any violation of anti-corruption laws or international
anti-money laundering laws or standard.
8] Affiliation with
Government :
No record
exists to suggest that any director or indirect owners, controlling
shareholders, director, officer or employee of the company is a government
official or a family member or close business associate of a Government official.
9] Compensation Package :
Our market
survey revealed that the amount of compensation sought by the subject is fair
and reasonable and comparable to compensation paid to others for similar
services.
10] Press Report :
No press reports / filings exists on
the subject.
CORPORATE GOVERNANCE
MIRA INFORM as part of its Due Diligence do provide comments on
Corporate Governance to identify management and governance. These factors often
have been predictive and in some cases have created vulnerabilities to credit
deterioration.
Our Governance Assessment focuses principally on the interactions
between a company’s management, its Board of Directors, Shareholders and other
financial stakeholders.
CONTRAVENTION
Subject is not known to have contravened any existing local laws,
regulations or policies that prohibit, restrict or otherwise affect the terms
and conditions that could be included in the agreement with the subject.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.07 |
|
|
1 |
Rs.78.78 |
|
Euro |
1 |
Rs.67.75 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest capability
for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General
unfavourable factors will not cause fatal effect. Satisfactory capability for
payment of interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Capability to overcome financial difficulties seems comparatively
below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
- |
NB |
New Business |
- |
This report is issued at your request without any
risk and responsibility on the part of MIRA INFORM PRIVATE LIMITED (MIPL)
or its officials.